Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Spartan Bioscience today announced that it has ... (MFDS) regulatory approval for its Spartan RX CYP2C19 ... than 60 minutes from a non-invasive cheek swab. , ... doctors to determine therapeutic strategies for drugs metabolized by ... the world’s most commonly prescribed drugs such as Plavix® ...
(Date:11/27/2014)... PITTSFIELD, Massachusetts, USA (PRWEB) November 26, 2014 ... with more accuracy, additive systems to enable 3D manufacture ... by analyzing road conditions are among finalists in nine ... Innovation . The awards are sponsored by SPIE, ... Photonics Media . , Winners will be announced ...
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... , Nov. 26, 2014 The announced sales ... the company is looking to expand in non-healthcare areas, ... The healthcare market research firm says that  Siemens is ... Information,s biennial survey of the IVD market , with ... change in its composition would likely affect IVD market ...
Breaking Biology Technology:Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... 7 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: What: ... Conference Call, When: ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... the address ...
... CA, Nov. 7 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX: NVN) ... 30, 2007. All amounts, unless,specified otherwise, are in Canadian ... million or $0.01 per share, for the,three months ended ... $2.3,million, or $0.03 per share, for the same period ...
... BioSpace, the leading biotech job,board and life ... pharmaceutical job seekers to the BioSpace Career Fair ... BioSpace Career Fair attracted a steady flow of ... from around the Maryland biotechnology cluster and Mid-Atlantic,region. ...
Cached Biology Technology:Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 3Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 4BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals 2
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
(Date:11/7/2014)... BURBANK, Calif. , Nov. 7, 2014  In conjunction ... Burbank Police Departments, The Community Foundation of the ... BURBANK DNA JUSTICE PROJECT," a $250,000 initiative to ... successful initial phase. In its first six months of existence, ... desperately needed evidence support for local law enforcement. ...
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3
... Scientists have moved closer to developing a universal flu vaccine ... study why some people seem to resist severe illness. ... samples just as the swine flu pandemic was getting underway ... flu seasons. They found that those who avoided severe ...
... several stages -- first by invading surrounding tissue, then ... circulating cells work their way out of the vascular ... initial process by which cancer cells enter the bloodstream ... escape blood vessels to permeate other tissues and organs ...
... study published in The Journal of Comparative Neurology ... science Michael Ariel, Ph.D., reported surprising findings about the ... head deep into their shell. While researchers expected ... animals with eyes on the side of their heads, ...
Cached Biology News:Scientists closer to universal flu vaccine after pandemic 'natural experiment' 2Microfluidic platform gives a clear look at a crucial step in cancer metastasis 2Microfluidic platform gives a clear look at a crucial step in cancer metastasis 3SLU researcher finds a turtle eye muscle adapts to deal with obstructed vision 2